Expression of p53, Bcl-2 and Bax in non-small cell lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 512s Year: 2007
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003
HER-2/neu oncoprotein expression in nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010
Correlation between expression of p53, pRb, mdm2, p21WAF1/CIP1, PCNA, cyclin D1 and apoptotic index (AI) in non-small cell lung cancer (NSCLC) cells Source: Annual Congress 2006 - Molecular pathology and genetics of lung cancer Year: 2006
Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017
N-terminal deletion augments the cell death-inducing activity of BAX in the adenoviral gene delivery to nonsmall cell lung cancers Source: Eur Respir J 2002; 20: Suppl. 38, 14s Year: 2002
p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007
Salinomycin suppresses TGF-ß1-induced EMT by down-regulating MMP-2,9 via AMPK-SIRT1 pathway in a non-small cell lung cancer Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017
BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer Source: Eur Respir J 2002; 19: 134-140 Year: 2002
Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer Source: Eur Respir J , 49 (4) 1600711; DOI: 10.1183/13993003.00711-2016 Year: 2017
Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer Source: Eur Respir J 2001; 17: 660-666 Year: 2001
FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009
Deguelin enhances chemosensitivity of non-small cell lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 336s Year: 2006
Choice of endogenous control for gene expression in nonsmall cell lung cancer Source: Eur Respir J 2005; 26: 1002-1008 Year: 2005
Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008